Recent News

• 04.09.2025 - Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
• 04.09.2025 - Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
• 04.07.2025 - Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
• 04.07.2025 - Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
• 03.31.2025 - Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
• 03.31.2025 - Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
• 03.19.2025 - New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
• 03.19.2025 - New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
• 03.12.2025 - Amarin Corporation’s Fourth Quarter & Full Year 2024 Results
• 03.12.2025 - Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program

Recent Filings

• 04.09.2025 - EX-99.1 EX-99.1
• 04.09.2025 - 8-K Current report
• 04.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.07.2025 - EX-99.1 EX-99.1
• 04.07.2025 - 8-K Current report
• 04.07.2025 - PRER14A Preliminary Proxy Soliciting materials
• 03.28.2025 - 8-K Current report
• 03.28.2025 - PRE 14A Other preliminary proxy statements
• 03.25.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership